Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases

Joaquín Manrique¹, Paolo Cravedi²
¹ Servicio de Nefrología. Complejo Hospital de Navarra. Pamplona (Spain)
² Icahn School of Medicine at Mount Sinai. New York (USA)

Nefrologia 2014;34(3):388-97

INTRODUCTION

Until the end of the Nineties, the treatment of glomerular diseases has been largely based on specific immunosuppressive agents, frequently associated with substantial toxicities. More recently, the development of monoclonal antibodies, together with progresses in the knowledge of pathophysiological mechanisms of autoimmune glomerulopathies, offered the opportunity for more selective, effective, and safer treatments.

Rituximab, a chimeric antibody against the B cell-expressed CD20 antigen, was the first monoclonal employed for the treatment of a glomerular disease.⁴ Introduced in 1998 with...
the indication for the treatment of non-Hodgkin lymphoma and chronic lymphatic leukemia, it has been subsequently approved as a therapy for rheumatoid arthritis. Rituximab has been initially used to treat membranous nephropathy (MN), but its use has rapidly spread to other primary and secondary glomerular diseases. Another antibody whose employment has progressively increased in the treatment of glomerulopathies is Eculizumab, a humanized monoclonal antibody against the C5 complement component.

These encouraging results and the growing availability of novel monoclonal antibodies selectively targeting cytokines, inflammatory mediators and different lymphocyte populations are expected to generate a major paradigm shift in the treatment of immune-mediated glomerular diseases.

RITUXIMAB

Membranous nephropathy

Membranous nephropathy, the leading cause of nephrotic syndrome in Caucasian adults, is characterized by the deposition of immune complexes in the subepithelial space of the glomeruli, leading to a thickening of the glomerular basement membrane. If untreated, about 30-40% of affected patients reach end-stage kidney disease (ESRD) in over 5-10 years after diagnosis.

Since B cells play a crucial role in MN pathogenesis through autoantibody production and antigen presentation, Rituximab was hypothesized to represent an ideal treatment to selective treat the disease. Consistent with this hypothesis, in early small cohort studies Rituximab-induced B-cell depletion was associated with proteinuria reduction and regression or amelioration of immunopathologic changes of active glomerular disease.

Recently, Ruggenenti et al. reported the outcomes of 100 patients with MN and nephrotic syndrome treated with Rituximab. B-cell depletion was associated with remission of the nephrotic syndrome in 65 out of 100 consecutive patients with MN. Twenty-seven of these patients achieved complete remission with reduction of urinary protein excretion to normal range, and 20 of the 35 who failed to achieve remission had their proteinuria reduced to less than 50% of baseline values. Treatment effect was time-dependent and all patients with at least four years of follow-up achieved complete or partial remission (Figure 1). Rituximab was effective also when previous treatments with steroids and other immunosuppressive drugs, including cyclophosphamide and chlorambucil, had failed or a second course of Rituximab was needed to treat disease recurrence after initial remission.

In summary, Rituximab treatment is able to achieve disease remission and to stabilize or even improve renal function in MN patients at high risk of poor outcome because of persistent nephrotic syndrome. In consideration of its excellent safety profile, Rituximab should be considered to replace more toxic regimens as first line treatment of MN, at least for those patients with nephrotic syndrome unresponsive to conservative therapy.

Minimal change disease and focal segmental glomerulosclerosis

Idiopathic Nephrotic Syndrome (NS) in children and young adults is secondary to minimal change disease (MCD) in 90 percent of cases and focal segmental glomerulosclerosis (FSGS) is present in most of the remaining ones. Except for a minority of cases associated with molecular defects of podocyte genes, the disease appears to be immune mediated. This represents the rationale why until recently treatment of the disease largely relied on steroids, that achieve remission within four weeks in approximately 90% of children with MCD and 20 to 60% of those with FSGS. Sixty to 70% of patients, however, relapse after steroid tapering or withdrawal and most require repeat courses of prednisone to achieve remission of recurrent episodes and/or the addition of other immunosuppressive medications such as calcineurin inhibitors, mycophenolate mofetil (MMF) or alkylating agents to reduce the number of relapses and prevent major side effects of steroid treatment. These patients are affected by the serious adverse effects of immunosuppression and by the serious complications associated with relapsing episodes of heavy proteinuria such as accelerated cardiovascular disease, thromboembolic events and progressive renal function loss.

The possibility of a specific and safer approach to patients with steroid-dependent or frequently relapsing NS emerged in 2004, when the B-cell depleting monoclonal antibody Rituximab was reported to induce remission of proteinuria in a child with frequently relapsing NS secondary to MCD who had received this medication to cure a supervened idiopathic thrombocytopenic purpura. Subsequent sparse uncontrolled observations reported the efficacy of Rituximab in patients with steroid-dependent or frequently relapsing MCD, suggesting that B-cell immunity could play a key role in the pathophysiology of the disease. A prospective cohort study tested the efficacy of multiple Rituximab infusions (1 to 5) in 46 consecutive children with idiopathic nephrotic syndrome lasting for at least 1 year and maintained in remission with oral prednisone and calcineurin inhibitors. Oral agents were tapered after each infusion, and completely withdrawn within 45 days. One- and 2-year-remission probabilities were, respectively, 20 and 10%, with Median time intervals between complete oral-agent withdrawal and relapse were 5.6 and 8.5 months, respectively, following the first and subsequent courses.

Until recently, less attention was given to adults and patients with FSGS given difficulties in designing adequately powered
In numerous small studies, Rituximab monotherapy proved effective in promoting complete remission of LN. In a series of 18 patients with NL class III/IV/V, induction therapy with Rituximab associated with MMF maintenance immunosuppression induced complete or partial remission in 78% of the cases, which persisted up to one year in 67% of them. This combined treatment seems effective also as a rescue therapy in refractory or relapsing LN forms. In an open-label, multicenter study including 15 patients with active or resistant LN, combined Rituximab-MMF therapy promoted partial or complete remission in 9 cases.

The results from initial uncontrolled studies were challenged by the Lupus Nephritis Assessment with Rituximab (LUNAR) trial, a randomized, double-blind, phase III study testing the efficacy and safety of Rituximab versus placebo in patients with active proliferative LN receiving MMF and steroids. The rates of complete or partial remission at 1 year (primary end point) in the Rituximab and placebo groups were 57% and 46%, respectively, which did not reach statistical significance. Nevertheless, Rituximab was associated with a significant improvement in C3, C4 and anti-dsDNA levels. The Exploratory Phase II/III SLE Evaluation of Rituximab trial also failed to demonstrate benefits on nonrenal lupus. However, uncontrolled studies on refractory LN still documented 75% responder rates and many specialists continue using Rituximab successfully for these patients. Further studies are needed to identify predictors of response to Rituximab in LN patients.

In lupus nephritis, ANCA-associated vasculitis, and cryoglobulinemic nephropathy

The crucial pathogenic role of immune complexes in lupus nephritis (LN) made this disease an obvious target for Rituximab therapy, with the rationale that B cell depletion will extinguish the reservoir of autoreactive plasma cells.
### Table 1. Main studies on monoclonal antibodies in glomerular diseases

<table>
<thead>
<tr>
<th>Reference</th>
<th>Ethiology</th>
<th>N</th>
<th>F/U (mo)</th>
<th>Study design</th>
<th>Dose</th>
<th>CR</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruggenenti P, et al., 2012&lt;sup&gt;a&lt;/sup&gt;</td>
<td>MN</td>
<td>100</td>
<td>29</td>
<td>Prospective cohort</td>
<td>375mg/m²; 1-4 doses</td>
<td>27%</td>
<td>PR: 38%; recurrences: 28%; Out of the 18 patients who completed 24-month follow-up, 4 were in complete remission, 12 was in partial remission, 1 had a limited response, and 1 patient relapsed. CR+PR=88%</td>
</tr>
<tr>
<td>Fervenza F, et al., 2010&lt;sup&gt;b&lt;/sup&gt;</td>
<td>MN</td>
<td>18</td>
<td>12</td>
<td>Prospective cohort</td>
<td>375mg/m²; 4 or 8 doses</td>
<td>22%</td>
<td>The study included only children. After steroid withdrawal, 9 patients relapsed, but 3 remained in remission without steroids for &gt;1yr</td>
</tr>
<tr>
<td>Kamei K, et al., 2009&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Steroid-dependent INS</td>
<td>12</td>
<td>12</td>
<td>Prospective cohort</td>
<td>375mg/m²; 1 dose</td>
<td>25%</td>
<td>The study included only children. Steroids were withdrawn after Rituximab infusion. Out of the 29 patients with &gt;2yrs follow-up, 12 (41%) remained in remission, 7 (24.1%) of them without further maintenance immunosuppression</td>
</tr>
<tr>
<td>Kemper MJ, et al., 2011&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Steroid-dependent INS</td>
<td>29</td>
<td>12</td>
<td>Retrospective</td>
<td>375mg/m²; 1-4 doses</td>
<td>70.3%</td>
<td>The study included only children. The study included only children. Steroids were withdrawn after Rituximab infusion. Out of the 29 patients with &gt;2yrs follow-up, 12 (41%) remained in remission, 7 (24.1%) of them without further maintenance immunosuppression</td>
</tr>
<tr>
<td>Ravani P, et al., 2013&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Multirelapsing INS</td>
<td>46</td>
<td>6</td>
<td>Off-on trial</td>
<td>375mg/m²; 1-5 doses</td>
<td>48%</td>
<td>The study included only children. The study included only children. The study included only children. The study included only children.</td>
</tr>
<tr>
<td>Ruggenenti P, et al., 2014&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Multirelapsing INS</td>
<td>30</td>
<td>12</td>
<td>Off-on trial</td>
<td>375mg/m²; 1-2 doses</td>
<td>100%</td>
<td>The study included adults (n=20) and children (n=10)&lt;sup&gt;a&lt;/sup&gt; At one year, 18 patients were treatment-free and 15 never relapsed</td>
</tr>
<tr>
<td>Kamei K, et al., 2014&lt;sup&gt;g&lt;/sup&gt;</td>
<td>Steroid-resistant INS</td>
<td>10</td>
<td>21</td>
<td>Retrospective</td>
<td>375mg/m²; 1-4 doses</td>
<td>70%</td>
<td>Rituximab was administered on top of steroids, calcineurin inhibitors ± antiproliferative agents. In 1 patient achieved PR and in 2 no response</td>
</tr>
<tr>
<td>Magnasco A, et al., 2012&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Steroid-resistant INS</td>
<td>31</td>
<td>3</td>
<td>RCT</td>
<td>375mg/m²; 2 doses</td>
<td>Ns</td>
<td>The study included only children. In the treatment arm, Rituximab was administered on top of previous immunosuppression and did not reduce proteinuria at 3 months</td>
</tr>
<tr>
<td>Pepper R, et al., 2009&lt;sup&gt;i&lt;/sup&gt;</td>
<td>LN III/IV/V</td>
<td>18</td>
<td>12</td>
<td>Prospective cohort</td>
<td>1g; 2 doses</td>
<td>78%</td>
<td>All patients were already on steroids and received Rituximab induction and MMF maintenance therapy</td>
</tr>
<tr>
<td>Rovin BH, et al., 2012&lt;sup&gt;j&lt;/sup&gt;</td>
<td>LN III/IV</td>
<td>144</td>
<td>12</td>
<td>RCT</td>
<td>1g; 4 doses</td>
<td>26%</td>
<td>Rituximab or placebo were administered together with MMF and steroids. No significant difference in Rituximab vs. placebo in overall (complete and partial) response rate 57% vs. 46%</td>
</tr>
<tr>
<td>Merrill JT, et al., 2010&lt;sup&gt;k&lt;/sup&gt;</td>
<td>LN II/III</td>
<td>257</td>
<td>12</td>
<td>RCT</td>
<td>1g; 4 doses</td>
<td>12%</td>
<td>Background immunosuppression was continued. No significant difference in Rituximab vs. placebo in overall (complete and partial) response rate 30% vs. 28%</td>
</tr>
<tr>
<td>Jones RB, et al., 2010&lt;sup&gt;l&lt;/sup&gt;</td>
<td>AAV</td>
<td>44</td>
<td>12</td>
<td>RCT</td>
<td>375mg/m²; 4 doses</td>
<td>76%</td>
<td>Patients were treated with steroids + Rituximab vs. intravenous cyclophosphamide. Remission rate was comparable between the two groups</td>
</tr>
<tr>
<td>Specks U, et al., 2013&lt;sup&gt;m&lt;/sup&gt;</td>
<td>AAV</td>
<td>197</td>
<td>18</td>
<td>RCT</td>
<td>375mg/m²; 4 doses</td>
<td>39%</td>
<td>Rituximab-induced rate of CR was not inferior to cyclophosphamide (33%)</td>
</tr>
</tbody>
</table>
The evidence that the percentage of circulating B cell correlates with ANCA-associated vasculitis activity formed the background for numerous uncontrolled studies where Rituximab induced disease remission in cases resistant to other treatments. In 2010, results have been published from two large randomized controlled trials, the Rituximab versus cyclophosphamide in ANCA-associated vasculitis (RITUXVAS) and the Rituximab in ANCA-Associated Vasculitis (RAVE) including 197 and 44 patients with ANCA-associated vasculitis, respectively. In both studies, Rituximab had a safety/efficacy profile similar to cyclophosphamide over 12 months of follow-up. Results from the extension phases of these studies might have major impact on future treatment of ANCA-associated vasculitis.

Rituximab proved effective also in the treatment of mixed cryoglobulinemia. A retrospective analysis of 242 patients with hepatitis C-unrelated mixed cryoglobulinemia showed that Rituximab treatment associated with steroids was associated with a significant improvement of clinical manifestations compared to steroids alone or in association with alkylating agents.

Continues Table 1. Main studies on monoclonal antibodies in glomerular diseases

<table>
<thead>
<tr>
<th>Reference</th>
<th>Ethiology</th>
<th>N</th>
<th>F/U (mo)</th>
<th>Study design</th>
<th>Dose</th>
<th>CR</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saadoun D, et al., 2010&lt;sup&gt;35&lt;/sup&gt;</td>
<td>HCV-MC</td>
<td>33</td>
<td>40</td>
<td>Prospective cohort</td>
<td>375mg/m²; 4 doses</td>
<td>81%</td>
<td>Patients and controls received also Peg-interferon-α and Ribavirin. Response rate was significantly higher than in the control group (40%)</td>
</tr>
<tr>
<td>Visentini M, et al., 2011&lt;sup&gt;36&lt;/sup&gt;</td>
<td>HCV-MC</td>
<td>27</td>
<td>7</td>
<td>Phase II clinical trial</td>
<td>250mg/m²; 2 doses</td>
<td>79%</td>
<td>Patients received also Peg-interferon-α and Ribavirin</td>
</tr>
<tr>
<td>Bomback AS, et al., 2012&lt;sup&gt;48&lt;/sup&gt;</td>
<td>DDD and C3 GN</td>
<td>6</td>
<td>12</td>
<td>Case series</td>
<td>900mg/w (w1-4), 1200 every 2w up to w53</td>
<td>33%</td>
<td>2 patients had a reduction in serum creatinine and 1 patient had proteinuria decline</td>
</tr>
<tr>
<td>Trachtman H, et al., 2011&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Steroid-resistant FSGS</td>
<td>16</td>
<td>3</td>
<td>Phase I clinical trial</td>
<td>0.3, 1, 2, or 4mg/kg; 1 dose</td>
<td>N/A</td>
<td>Fresolimumab was well tolerated</td>
</tr>
<tr>
<td>Joy MS, et al., 2010&lt;sup&gt;31&lt;/sup&gt;</td>
<td>FSGS</td>
<td>10</td>
<td>4</td>
<td>Phase I clinical trial</td>
<td>24mg/m²; 9 doses</td>
<td>N/A</td>
<td>Adalimumab was well tolerated. Proteinuria decreased by ≥50% in 4 of 10 treated patients</td>
</tr>
<tr>
<td>Yu CC, et al., 2013&lt;sup&gt;32&lt;/sup&gt;</td>
<td>FSGS</td>
<td>5</td>
<td>10-48</td>
<td>Case series</td>
<td>10mg/kg; 1-3 doses</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>Navarra SV, et al., 2011&lt;sup&gt;53&lt;/sup&gt;</td>
<td>SLE</td>
<td>867</td>
<td>12</td>
<td>RCT</td>
<td>1 or 10mg/kg</td>
<td></td>
<td>Significantly higher rates of reduction of SLE severity index in Belimumab treatment groups vs. placebo. LN was an exclusion criterion</td>
</tr>
</tbody>
</table>

<sup>a</sup> Rituximab was added when patients were in remission with other therapies that were progressively withdrawn. The rate of remission refers to the patients with no therapy at 2 years after Rituximab.

showed that two 250mg/m² Rituximab infusions (about half of the doses normally used) induced remission in 79% of the cases of mixed cryoglobulinemia resistant to other therapies. Reducing Rituximab doses may therefore help in improving the safety/efficacy profile of this antibody, at least in the treatment of mixed cryoglobulinemia.

**Safety**

Rituximab is generally well tolerated and to date no serious adverse events have been reported in patients affected by glomerular diseases treated with Rituximab monotherapy. Amongst the millions of patients treated so far, rare cases of progressive multifocal leukoencephalopathy (PML) have been described in patients affected by autoimmune diseases who received Rituximab as a component of multidrug immunosuppressive regimens. In none of these cases, however, Rituximab has been clearly identified as responsible in promoting this infection, especially if we consider that affected patients were on active or previous treatment with other immunosuppressants. Moreover, this infection may occur also in patients with autoimmune disease treated with Rituximab-free immunosuppressive regimens. Conversely, this infection has never been reported in Rituximab-treated patients who never received other immunosuppressants.

**Optimal dosing**

Treatment protocols varied widely amongst different centers. Some authors used the standard regimen of four 375mg/m² weekly doses, others preferred an eight-dose “prolonged protocol” or an “extended protocol” in which the standard four weekly infusions were followed by two or three monthly infusions. Interestingly, serial measurements of circulating B-cells showed that, in patients with MN or lupus, CD20 cells were fully depleted from the circulation just after the first drug administration. Consistently, in a 2 years follow up study, Fervenza et al. found no difference in proteinuria reduction at 12 months in MN patients treated with two courses of four 375mg/m² Rituximab doses compared to those who received a single course or two doses of 1g. These findings led to question whether further Rituximab doses confer additional benefit or, rather, may just increase the risk of adverse reactions or sensitization. To address this issue, a prospective, matched-cohort study compared the safety/efficacy profile of a B-cell-driven Rituximab treatment with the standard four 375mg/m² dose protocol in 36 MN patients with long-lasting nephrotic range proteinuria refractory to conventional therapy. Patients allocated to the B-cell-driven protocol received a second infusion only if they had more than five B-cells per mm³ of peripheral blood after the first Rituximab administration, which occurred in only one of the 12 patients in this group. Prompt and persistent B-cell depletion was achieved in all patients. Time-dependent changes in proteinuria and the other components of the nephrotic syndrome were similar in the two groups. However, the B-cell-driven approach was associated with fewer adverse events and less hospitalizations, and was four-fold less expensive, allowing for more than €10,000 (approximately $13,000) savings per patient. Thus, B-cell titrated dosing, in addition to improve the risk/benefit profile of the drug, may facilitate the access to Rituximab even in resource-limited settings.

**ECULIZUMAB**

Eculizumab is an inhibitor of C5 complement component, initially approved by Food and Drug Administration and European Medical Agency for the treatment of Paroxysmal Nocturnal Hemoglobinuria, a potentially fatal disease characterized by complement-mediated hemolysis due to the absence of CD59, a C3 convertase inhibitor, on the erythrocyte membrane.

More recently, Eculizumab has been approved also for the treatment of atypical hemolytic-uremic syndrome (aHUS), a condition where abnormalities in the genes encoding for complement inhibitors may lead to uncontrolled complement activation and to the formation of microthrombi in glomeruli. A review of the published literature revealed five individual case reports describing the use of Eculizumab for the treatment of membranoproliferative glomerulopathy (MPGN); two patients diagnosed with MPGN Type I and three patients with MPGN Type II (DDD). Reports of the first two patients with aHUS successfully treated with Eculizumab were published in 2009. The first case was an 18-month old baby with non-identified genetic defect resistant to plasma therapy, where a 4-month treatment with Eculizumab induced disease remission. In a second patient of 37 years with a deficit in factor H, a single 600mg Eculizumab dose was enough to treat disease recurrence after kidney transplant. These reports have been followed by many others, where Eculizumab has been used to treat primary aHUS and for the treatment of post-transplant recurrences. In two recent prospective trials, Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with aHUS. These data indicate that terminal complement inhibition with Eculizumab inhibits complement-mediated thrombotic microangiopathy, decreases the need for thrombotic microangiopathy-related intervention, significantly improves the platelet count and renal function across patient groups, and is associated with substantial kidney recovery and improved clinical outcomes in patients with aHUS.

These data support the use of Eculizumab for the treatment of aHUS and, as recently reported, also in the most severe cases of typical HUS associated with shiga-toxin producing bacteria. Extremely high costs of this antibody, however, will
force world healthcare systems to confront and contemplate the economical sustainability of this treatment.

**Dense deposit disease and C3 nephropathy**

Dense deposit disease (DDD), also named type II MPGN, is characterized by the presence of electron dense material within glomerular basement membrane. This nephropathy is associated with an abnormal activation of complement alternative pathway secondary to genetic mutations in complement regulators or to the presence of autoantibodies inhibiting complement regulator activity. Eculizumab has been used to block complement activation in patients with DDD. In five cases, treatment was effective in reducing proteinuria, improving renal function, and histological lesions during one-year follow-up. In a sixth patient with DDD recurrence in the transplanted kidney, Eculizumab induced proteinuria remission after treatment with plasmapheresis, steroids, and Rituximab failed. Eculizumab was employed also in three patients with C3 nephropathy, a disease characterized by the presence of subepithelial or mesangial electron dense deposits, and in two cases promoted renal function improvement or stabilization.

Recently, an 8-year-old child with C3 nephropathy and refractory DDD who presented with a nephritic syndrome was successfully treated with Eculizumab, after multiple treatments, including steroids and Rituximab, failed.

These initial experiences support the use of Eculizumab in patients affected by glomerulopathies secondary to complement alterations. On the other hand, the presence subjects resistant to this treatment suggest the existence of pathogenic elements alternative to complement dysregulation, at least in a minority of patients with DDD or C3 nephropathy. The study of these patients might therefore prove important for the understanding of the pathophysiology of these nephropathies and the definitions of new therapies. This is a crucial aspect of any treatment with monoclonals that, in contrast with other drugs lacking a specific mechanism of action, have the major advantage of providing helpful information regarding pathogenesis even in the cases where they are ineffective.

**Safety**

So far, Eculizumab has been administered to more than 1,000 patients with various indications. Reported adverse effects have been numerous, but of mild severity. The most severe adverse effect is linked to the Eculizumab-induced complement inhibition that increases the risk of infections by meningococcus, a capsulate microorganism whose clearance is largely based on complement activity. This risk can be prevented by vaccinating patients before Eculizumab exposure and by performing a prophylaxis with penicillin during the treatment period. Up to date, no strain of meningococcus resistant to this antibiotic has been reported.

**Fresolimumab**

TGF-β1 has been long considered a key mediator of renal fibrosis by activating its downstream Smad signaling pathway. More recently, TGF-β has been recognized also as a key regulator of podocyte function. Both FSGS patients and experimental models of the disease demonstrate increased expression of TGF-β in the kidney and in the urine. Overexpression of TGF-β in podocytes leads to podocytopenia and glomerulosclerosis. In cultured podocytes, TGF-β influences cell survival and induces changes in the cytoskeleton and cell adhesion that are analogous to in vivo foot process effacement. These findings suggest that targeting TGF-β in the kidney may be renoprotective and have a beneficial effect on the severity or progression of FSGS.

Fresolimumab is a humanized monoclonal antibody able to neutralize all three isoforms of TGF-β. A phase I clinical trial in 16 patients with treatment-resistant primary FSGS and nephrotic-range proteinuria showed that Fresolimumab is well tolerated and is associated with a trend toward proteinuria reduction, especially in black patients. A larger phase II trial is testing the safety/efficacy profile of Fresolimumab versus placebo in 88 patients with steroid-resistant FSGS (ClinicalTrials.gov: NCT01665391).

**Adalimumab**

Tumor necrosis factor-α (TNF-α) is an inflammatory cytokine produced by a wide range of cells including macrophages and renal tubular epithelial cells. TNF-α has been implicated in the pathogenesis of proteinuria in FSGS through recruitment of leukocytes to the glomeruli, induction of cytokines and growth factor release, generation of oxygen radicals, and induction of cell apoptosis. Consistently, experimental models of FSGS and affected patients display high renal TNF-α and TNF-α produced by mononuclear cells of FSGS patients induces proteinuria in animals. Importantly, TNF-α antagonism reduced proteinuria in the angiotensin II-induced renal injury model and other models that resemble FSGS.

A phase I study showed that 16 weeks of treatment with Adalimumab, a monoclonal antibody against TNF-α, promoted a stabilization of renal function and a reduction in proteinuria in 10 patients with steroid-resistant FSGS. A phase II study is testing the safety/efficacy profile in a larger cohort of patients with steroid-resistant FSGS (NCT00814255).
ABATACEPT

Various animal models of proteinuria are associated with an upregulation of B7-1 (CD80) in podocytes. B7-1 expression is not evident in normal human kidney podocytes but is found in patients with glomerular diseases. Yu et al. recently introduced a new classification of proteinuric kidney diseases by dividing them into B7-1-positive or B7-1-negative. These authors found that B7-1-positive podocytes have a reduced capacity to attach to the surrounding matrix through β1 integrin. B7-1-positive podocytes change their morphologic characteristics and their function, leading to detachment of their foot processes from the glomerular basement membrane and giving rise to proteinuria. A large randomized placebo-controlled trial (BLISS-52) of 867 patients with erythematous lupus showed that add-on Belimumab on top of standard maintenance therapy significantly improved persistent disease activity up to 72 weeks. This study led to the US Food and Drug Administration and European Medicines Agency approval of Belimumab for nonrenal lupus. The specific effect of the addition of Belimumab on renal function or proteinuria among patients with renal involvement was not described. This study demonstrated a beneficial effect of Belimumab in addition to standard immunosuppression in patients with SLE. The currently available data do not address its effect on renal disease. Whether Belimumab has a role in the treatment of LN, especially when associated with moderate to severe renal dysfunction, or rapid loss of function is unknown and still awaits ad hoc studies. However, promising data from patients with moderate nephritis enrolled in the BLISS-56 trial raise hope that Belimumab could also be efficient in severe LN.

BELIMUMAB

Belimumab is a humanized monoclonal antibody that binds to soluble human BLyS and inhibits its biologic activity, which eventually restrains B cell proliferation. A large randomized placebo-controlled trial (BLISS-52) of 867 patients with erythematous lupus showed that add-on Belimumab on top of standard maintenance therapy significantly improved persistent disease activity up to 72 weeks. This study led to the US Food and Drug Administration and European Medicines Agency approval of Belimumab for nonrenal lupus. The specific effect of the addition of Belimumab on renal function or proteinuria among patients with renal involvement was not described. This study demonstrated a beneficial effect of Belimumab in addition to standard immunosuppression in patients with SLE. The currently available data do not address its effect on renal disease. Whether Belimumab has a role in the treatment of LN, especially when associated with moderate to severe renal dysfunction, or rapid loss of function is unknown and still awaits ad hoc studies. However, promising data from patients with moderate nephritis enrolled in the BLISS-56 trial raise hope that Belimumab could also be efficient in severe LN.

Acknowledgments
We are indebted to Jesus Arteaga and Jeremy Leventhal for their helpful suggestions.

Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.

KEY POINTS

1. Growing availability of monoclonal antibodies is quickly changing the way immune mediated glomerular diseases are treated and is helping translating in the clinical practice results from basic research pathophysiology studies.

2. Results from prospective trials consistently showed that anti-CD20 depleting antibody Rituximab safely reduced proteinuria in patients with nephrotic syndrome associated with membranous nephropathy and multirelapsing minimal change disease or FSGS.

3. Eculizumab, a monoclonal antibody targeting the complement component C5, has become standard of care treatment for atypical hemolytic uremic syndrome and C3 nephropathy.

4. Encouraging results from small, pilot studies are showing the efficacy of Abatacept (CTLA4-Ig), Adalimumab (anti-TNF-α), Belimumab (anti-BLyS), Fresolimumab (anti-TGF-β) in reducing proteinuria in different glomerular diseases, including FGSG and lupus nephritis.

5. Due to the high costs of monoclonals, identification of optimal doses to use in glomerular diseases will be instrumental for their clinical implementation, especially in resource-limited settings.
REFERENCES


